Orphan Europe has a product portfolio of ten products treating different rare diseases. Most of these products have a European orphan drug designation and have a European marketing authorization (you will find more information to your left). Some of our products are still under clinical development or are currently in the process of registration. These products are distributed to patients at the request of the treating physicians under a “named patient use” regulation. All Orphan Europe’s products are distributed all over the world direct to the patient’s hospital or local pharmacy from our distribution department in Paris

Please do not hesitate to contact Orphan Europe for further information about our products.